You need to enroll in this course to view this chapter
Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study
0% Course Complete
Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study Attachments
100%
Page 1 of ?/?
Go to:
Loading PDF...